These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16403907)

  • 1. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18.
    Liu H; Zang C; Fenner MH; Liu D; Possinger K; Koeffler HP; Elstner E
    Blood; 2006 May; 107(9):3683-92. PubMed ID: 16403907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines.
    Zang C; Liu H; Waechter M; Eucker J; Bertz J; Possinger K; Koeffler HP; Elstner E
    Cell Cycle; 2006 Oct; 5(19):2237-43. PubMed ID: 17102607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.
    Liu DC; Zang CB; Liu HY; Possinger K; Fan SG; Elstner E
    Acta Pharmacol Sin; 2004 Oct; 25(10):1312-9. PubMed ID: 15456533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor alpha/gamma, in human breast cancer cells.
    Zang C; Liu H; Bertz J; Possinger K; Koeffler HP; Elstner E; Eucker J
    Mol Cancer Ther; 2009 Aug; 8(8):2296-307. PubMed ID: 19671747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The administration of peroxisome proliferator-activated receptors α/γ agonist TZD18 inhibits cell growth and induces apoptosis in human gastric cancer cell lines.
    Ma Y; Wang B; Li L; Wang F; Xia X
    J Cancer Res Ther; 2019; 15(1):120-125. PubMed ID: 30880766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PPARα/γ ligand TZD18 improves myocardial metabolic remodeling after myocardial infarction in rats.
    Chen XL; Liu ZR; Xue YJ; Chen X
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5765-5773. PubMed ID: 29272013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells.
    Han S; Sidell N; Fisher PB; Roman J
    Clin Cancer Res; 2004 Mar; 10(6):1911-9. PubMed ID: 15041706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.
    Bertz J; Zang C; Liu H; Wächter M; Possinger K; Koeffler HP; Elstner E
    Leuk Res; 2009 May; 33(5):686-92. PubMed ID: 19131110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma.
    Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH
    Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
    Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
    Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
    Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
    Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
    Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y; Rahmani M; Pei XY; Dent P; Grant S
    Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.
    Zang C; Liu H; Posch MG; Waechter M; Facklam M; Fenner MH; Ruthardt M; Possinger K; Phillip Koeffler H; Elstner E
    Leuk Res; 2004 Apr; 28(4):387-97. PubMed ID: 15109539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
    Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
    Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
    Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
    Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells.
    Glodkowska-Mrowka E; Manda-Handzlik A; Stelmaszczyk-Emmel A; Seferynska I; Stoklosa T; Przybylski J; Mrowka P
    Blood Cancer J; 2016 Jan; 6(1):e377. PubMed ID: 26745851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.